ESR1 and breast cancer: Obtaining circulating DNA from liquid biopsies conserves the genomic landscape of the tumor suggesting that this less invasive detection methods may efficiently identify ESR1 fusions, particularly in metastatic ET resistant ER+ breast cancer.